Mould found in nearly half the Royal Canadian Navy's frigates
Article content
Cheryl Forrest, who speaks for National Defence, confirmed that mould has been found in five frigates, the most recent on HMCS Vancouver this year.
Article content
'Small amounts of mould have been reported in two areas of high humidity on HMCS Vancouver recently and were quickly removed and the areas cleaned,' Forrest said in an email. 'This also resulted in enhanced inspections of similar areas of concern on the ship with no other mould areas reported.'
Article content
The other contaminated ships are HMCS St. John's in 2011, HMCS Calgary in 2018, HMCS Halifax and HMCS Charlottetown in 2019.
Article content
Article content
While Forrest didn't mention it, a report from the Directorate of Force Health Protection released in 2018 indicates an air quality assessment aboard HMCS Winnipeg found higher-than-normal levels of mould spores in three compartments while the frigate was sailing from Tokyo to Hawaii in July 2017.
Article content
The mould was removed from 'affected frigates,' Forrest said. 'Technical enhancements were completed to improve air quality. If mould recurs, ships have been directed to clean and report it immediately.'
Maritime and shipboard environments can be humid and warm, which makes them naturally prone to mould, she said.
Article content
The issue of mould in the Halifax-class warships made headlines recently when a Federal Court judge shot down a proposed class action case led by a former Royal Canadian Air Force captain who claimed 'dangerous levels of toxic mould' in HMCS Vancouver caused him serious ongoing health problems. The judge ruled Félix Dunn, an air combat systems officer who was stationed aboard the warship from June until December of 2016, couldn't sue the federal government over the mould issue because Veterans Affairs Canada had already compensated him for the same injury.
Article content
Article content
Forrest said the military has developed an air quality program for the frigates 'to support a safe working environment.'
Article content
Article content
'This involves the Canadian Forces Deployable Health Hazard Assessment Team onboard a Halifax Class frigate each year for a period of two weeks to undertake an indoor air quality assessment throughout the ship. Collected samples are tested by an independent laboratory to determine if mould spores are present in a greater quantity than a sample of outdoor air reference sample.'
Article content
HMCS Ville de Quebec 'was surveyed (last October) and no significant mould issues were identified,' Forrest said. 'HMCS Vancouver has been selected to have this survey undertaken during 2025.'
Article content
Inspection and cleaning routines for the ventilation trunking, or ductwork in the frigates, happens on a five-year schedule, she said. 'Areas which are prone to high humidity (such as places where food is served and prepared, and washrooms) are inspected and cleaned more frequently (on a 12-month or a 24-month schedule).'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
a day ago
- CBC
Research on gene therapy for rare inherited disease reduces costly, regular treatment
A researcher says the experimental use of gene therapy for a rare inherited disorder is saving almost as much money for treatment of five patients as the study itself costs. The early-stage study published last year found that three of the men being treated for Fabry disease were able to stop using enzyme-replacement therapy — which costs about $300,000 annually — once they started on the "one-time" gene therapy. Dr. Michael West, a co-author and kidney specialist in Halifax, says the overall savings have been $3.7 million, against research costs to date of about $4 million — which was largely provided by the federal Canadian Institutes of Health Research. Fabry disease is a rare disorder that leaves the body unable to produce the correct version of an enzyme that breaks down fatty materials — leading to major damage to vital organs and shortened lifespans. Some people suffer various symptoms including pain in their hands and feet, intestinal problems and chronic fatigue. Stem cells The gene therapy uses the stem cells taken from the men's bone marrow to deliver a replacement copy of the faulty gene. The research team wrote in the Journal of Clinical and Translational Medicine last year that one of the men with advanced kidney disease saw his condition stabilize, and the researchers also found that none of the men had major events such as heart attacks or kidney failure caused by Fabry over the last five years, West said. "These patients are still producing more of the needed enzymes than they did prior to the gene therapy," said the 72-year-old physician, who works at the Queen Elizabeth II Health Sciences Centre in Halifax and is a professor at Dalhousie University. West said in other instances of gene therapy there's been instances of severe side effects from procedures, including the development of various forms of cancer. However, West said since the men received their gene therapy for Fabry between 2016 and 2018, there has been just two instances of side effects, neither of which were a direct result of the therapy itself. Rather, in one case, a chemotherapy drug used to "make space" in bone marrow for grafting in modified cells caused a man's white blood cell count to fall. He was treated with antibiotics for a potential infection and recovered, West said. In a second case, a man developed a large bruise in his leg, which the researchers believe was due to possible side effects of the chemotherapy drug. Worth the effort West said while the research needs to go to larger-scale studies before it becomes conventional treatment, he believes it's worth pursuing due in part to the costs and "the burden to patients" of the existing therapy. The specialist said that conventional enzyme-replacement therapy has to occur every two weeks, requiring approximately two hours for each treatment. Out of the roughly 540 people with Fabry in Canada, the researcher says about 100 are in Nova Scotia. It's believed the first person with the genetic mutation can be traced back to a French woman who immigrated to Lunenburg, N.S., in the colonial era, and her descendants carried the faulty gene through 18 generations that followed. "Currently, there's some cases in Ontario, there's some in British Columbia, there's some in the U.K., some cases in Florida, but they all originated from here and they share the same mutation," West said. Cost unknown West said the ultimate cost of gene therapy per patient has yet to be determined, as it first would have to be approved by the major regulatory agencies as an accepted treatment. But he said one option for inherited genetic diseases, where there is a relatively small group of patients, would be for government research agencies to develop and own the treatment themselves, and then earn fees to provide the treatments to other national health systems. West said he realizes the sample size is small, and the goal is now to create a similar study with 25 to 30 patients, including women, over a two- to three-year period.
CTV News
a day ago
- CTV News
Research on gene therapy for rare inherited disease reduces costly, regular treatment
Dr. Michael West, a co-author and Dalhousie University researcher, is shown in this handout image. THE CANADIAN PRESS/Handout HALIFAX — A researcher says the experimental use of gene therapy for a rare inherited disorder is saving almost as much money for treatment of five patients as the study itself costs. The early-stage study published last year found that three of the men being treated for Fabry disease were able to stop using enzyme-replacement therapy — which costs about $300,000 annually — once they started on the 'one-time' gene therapy. Dr. Michael West, a co-author and kidney specialist in Halifax, says the overall savings have been $3.7 million, against research costs to date of about $4 million — which was largely provided by the federal Canadian Institutes of Health Research. Fabry disease is a rare disorder that leaves the body unable to produce the correct version of an enzyme that breaks down fatty materials — leading to major damage to vital organs and shortened lifespans. Some people suffer various symptoms including pain in their hands and feet, intestinal problems and chronic fatigue. The gene therapy uses the stem cells taken from the men's bone marrow to deliver a replacement copy of the faulty gene. The research team wrote in the Journal of Clinical and Translational Medicine last year that one of the men with advanced kidney disease saw his condition stabilize, and the researchers also found that none of the men had major events such as heart attacks or kidney failure caused by Fabry over the last five years, West said. 'These patients are still producing more of the needed enzymes than they did prior to the gene therapy,' said the 72-year-old physician, who works at the Queen Elizabeth II Health Sciences Centre in Halifax and is a professor at Dalhousie University. West said in other instances of gene therapy there's been instances of severe side effects from procedures, including the development of various forms of cancer. However, West said since the men received their gene therapy for Fabry between 2016 and 2018, there has been just two instances of side effects, neither of which were a direct result of the therapy itself. Rather, in one case, a chemotherapy drug used to 'make space' in bone marrow for grafting in modified cells caused a man's white blood cell count to fall. He was treated with antibiotics for a potential infection and recovered, West said. In a second case, a man developed a large bruise in his leg, which the researchers believe was due to possible side effects of the chemotherapy drug. West said while the research needs to go to larger-scale studies before it becomes conventional treatment, he believes it's worth pursuing due in part to the costs and 'the burden to patients' of the existing therapy. The specialist said that conventional enzyme-replacement therapy has to occur every two weeks, requiring approximately two hours for each treatment. Out of the roughly 540 people with Fabry in Canada, the researcher says about 100 are in Nova Scotia. It's believed the first person with the genetic mutation can be traced back to a French woman who immigrated to Lunenburg, N.S., in the colonial era, and her descendants carried the faulty gene through 18 generations that followed. 'Currently, there's some cases in Ontario, there's some in British Columbia, there's some in the U.K., some cases in Florida, but they all originated from here and they share the same mutation,' West said. West said the ultimate cost of gene therapy per patient has yet to be determined, as it first would have to be approved by the major regulatory agencies as an accepted treatment. But he said one option for inherited genetic diseases, where there is a relatively small group of patients, would be for government research agencies to develop and own the treatment themselves, and then earn fees to provide the treatments to other national health systems. West said he realizes the sample size is small, and the goal is now to create a similar study with 25 to 30 patients, including women, over a two- to three-year period. This report by The Canadian Press was first published July 4, 2025. By Michael Tutton
CTV News
2 days ago
- CTV News
‘All types are needed': Canadian Blood Services urges people to donate this summer
Canadian Blood Services chats about the increased need for blood donations during the summer months. Canadian Blood Services chats about the increased need for blood donations during the summer months. Canadian Blood Services is asking people to roll up their sleeves and donate this summer as the organization deals with an increased need. Halifax-based community development manager Krysta Hanakowski says there are a few times a year where it's harder than others to collect blood. 'And summer is the worst, and that's because Nova Scotia's beautiful, there's a lot of other things to do in the summer. Our regular donors are away on vacation, so it's just a real struggle to collect,' she told CTV Atlantic's Crystal Garrett. 'In addition to that, there's also numerous long weekends, so we have long weekends in July, August and September, and long weekends are also notoriously difficult to collect blood on.' Hanakowski says demand is actually higher now than it has been at any point in the past 10 years. 'Demand is only increasing and, as well, in Nova Scotia, we have a population that's both aging and growing, so all those things put together mean that we just need more people to come donate,' she says. Canadian Blood Services says there isn't a type of blood that it doesn't need, and Hanakowski points to the misconception that you need to know your blood type before you donate. 'You don't need to know that. After you donate, we will give you a card with your blood type on it, but all types are needed,' she says. 'You'll hear especially a cry for o-negative blood all the time, and that's because it's used more than others in an emergency situation – they're just going to give people o-negative blood because it's safe for everyone.' Even if you donate once, it doesn't last forever. Red blood cells can only be stored for up to 42 days. 'And we have blood going from our clinic to our lab to the hospitals every day, so that's why we constantly need people in and donating to help replenish the product, we're open six days a week in Halifax, we're only closed on Sundays, so there's lots of opportunities for people to come out and help.' Men can donate every 56 days and women can donate blood every 84 days. Hanakowski says it's a great opportunity because that means everybody can come and donate once this summer. 'We're only asking for one hour of people's time over the course of summer, so plan a fun summer, but try and give us that one hour and come experience kind of how you feel after helping save somebody's life,' she says. Even if a person can't donate themselves, Hanakowski adds there are other ways to help. 'We'd love people to help recruit other donors, have the conversation with your friends and family to help us keep it top of mind for people,' she says. 'You can follow us on socials, help spread the news there, and if you're 17 to 35 you can also join the stem cell registry. You can give financially, you can come and volunteer, there's lots of ways to become involved outside of donating blood.' People can book an appointment on the GiveBlood app or call 1 888 2 DONATE (1-888-236-6283). For more Nova Scotia news, visit our dedicated provincial page
